VC
WHWK

Vivo Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Vivo Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-509,572
Closed -$744K – 46
2024
Q2 		$744K Hold
509,572
– – 0.07% 40
2024
Q1 		$1.19M Hold
509,572
– – 0.09% 41
2023
Q4 		$1.03M Hold
509,572
– – 0.08% 45
2023
Q3 		$6.46M Hold
509,572
– – 0.71% 33
2023
Q2 		$6.46M Hold
509,572
– – 0.45% 32
2023
Q1 		$6.46M Hold
509,572
– – 0.45% 30
2022
Q4 		$6.54M Hold
509,572
– – 0.75% 29
2022
Q3 		$7.2M Hold
509,572
– – 0.79% 33
2022
Q2 		$6.28M Sell
509,572
-262,844
-34% -$3.9M 0.63% 34
2022
Q1 		$13.1M Sell
772,416
-530,974
-41% -$10.2M 0.9% 26
2021
Q4 		$31.5M Sell
1,303,390
-123,823
-9% -$3.11M 1.9% 14
2021
Q3 		$41.9M Buy
+1,427,213
New +$43.5M 1.88% 13

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital's WHWK Position: Q3 2024 in Review

Vivo Capital sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 509,572 shares — an estimated $744K sold.

Vivo Capital first reported a position in WHWK in Q3 2021 and held it in 12 quarters. The position peaked at $41.9M in Q3 2021. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • Vivo Capital reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Vivo Capital sold 509,572 Whitehawk Therapeutics shares in Q3 2024, an estimated $744K.
  • Vivo Capital first reported a position in Whitehawk Therapeutics in Q3 2021 and held it in 12 quarters.
  • Vivo Capital's Whitehawk Therapeutics position peaked at $41.9M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on Vivo Capital's 13F filing for Q3 2024, filed 13 Nov 2024.